---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-23-000036"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:32:03.242149+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jazz Pharma Q2 revenue $957M (+3% YoY); GAAP EPS $1.52 beats; raises FY guidance

## Summary
- Q2 total revenue $957M (+3% YoY); GAAP net income $104.4M ($1.52 diluted EPS) vs $34.7M ($0.55) prior year.
- Xywav sales $326.6M (+39% YoY); Epidiolex $202.2M (+15%); Rylaze $101.7M (+39%).
- Raises FY2023 guidance: revenue $3.725-$3.875B; non-GAAP adjusted EPS raised to $18.15-$19.00 from $16.90-$17.85.
- Repurchased $100M in shares under $1.5B program; $336M remaining as of June 30, 2023.
- Combined oxybate revenue (incl. AG royalties) $491.8M (-2% YoY); Xyrem down 41% to $159.8M.

## SEC filing metadata
- accession: 0001232524-23-000036
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/0001232524-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/jazz-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-23-000036
- JSON: https://secwatch.observer/filing/0001232524-23-000036.json
- Plain text: https://secwatch.observer/filing/0001232524-23-000036.txt

## Key facts
- Earnings Releases
  Jazz Pharmaceuticals plc updated its the second quarter of 2023 guidance (raised).
  - Period: the second quarter of 2023
  - Guidance: raised
  - Result: reported results
  source text: On August 9, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1232524/000123252423000036/0001232524-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.